Menu
B

Benchmark Research | Sacramento, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ritonavir
EYE201
EYE103
Peramivir
Fluticasone Proprionate
Ranibizumab
Lubiprostone
Ulipristal Acetate
Ciprofloxacin
Olopatadine

Parent organization

This site is a part of Benchmark Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201.All participants in the study w...

Enrolling
BRVO - Branch Retinal Vein Occlusion
Diabetic Macular Edema (DME)
Drug: EYE201

This phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult...

Enrolling
Encephalitis
Biological: MVA-BN-WEV
Other: Placebo

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting
COVID-19
Biological: mRNA-1283.222
Biological: mRNA-1273.815

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Enrolling
Diabetic Macular Edema (DME)
Drug: EYE103
Drug: Ranibizumab

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Enrolling
Lower Respiratory Tract Illness
Biological: RSVpreF
Biological: Placebo
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trial sponsors

Pfizer logo
Moderna logo
E
MedImmune logo
Novavax logo
Janssen (J&J Innovative Medicine) logo
Alcon logo
Bavarian Nordic logo
BioCryst logo
BioNTech logo